Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 611 to 620 of 797

TitleReference numberPublishedLast updated
Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritisTA373
Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapyTA374
Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis CTA365
Vortioxetine for treating major depressive episodesTA367
Ledipasvir–sofosbuvir for treating chronic hepatitis CTA363
Tolvaptan for treating autosomal dominant polycystic kidney diseaseTA358
Idelalisib for treating chronic lymphocytic leukaemiaTA359
Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal)TA362
Vedolizumab for treating moderately to severely active Crohn's disease after prior therapyTA352
Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal)TA353

Results per page

  1. 10
  2. 25
  3. 50
  4. All